Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
130,004,988
-
Share change
-
+2,187,099
-
Total reported value
-
$980,205,355
-
Put/Call ratio
-
20%
-
Price per share
-
$7.54
-
Number of holders
-
180
-
Value change
-
+$10,218,308
-
Number of buys
-
86
-
Number of sells
-
86
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q1 2023
As of 31 Mar 2023,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
180 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
130,004,988 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, BlackRock Inc., Voya Investment Management LLC, BAKER BROS. ADVISORS LP, Capital World Investors, CREDIT SUISSE AG/, ORBIMED ADVISORS LLC, HARVARD MANAGEMENT CO INC, Founders Fund VII Management, LLC, and STATE STREET CORP.
This page lists
181
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.